Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118


Survival benefits of oral anticoagulants in patients with pulmonary arterial hypertension: Protocol for a systematic review and meta-analysis.

Zhang HC, Wang N, Zhang W, Gu ZC, Liu XY.

Medicine (Baltimore). 2018 Sep;97(36):e12203. doi: 10.1097/MD.0000000000012203. Review.


A case report of pulmonary arterial hypertension in pregnancy and complications of anticoagulation therapy.

Xiang Y, Li J, Sun Y.

Medicine (Baltimore). 2018 Aug;97(32):e11810. doi: 10.1097/MD.0000000000011810.


Role of Noncoding RNA in Pulmonary Arterial Hypertension and Potential Drug Therapeutic Target.

Zhang CY, Liu M, Wan JM, Gao MQ, Zhang Y, Soyan M, Wang HL, Bai Y.

Curr Top Med Chem. 2018;18(12):975-986. doi: 10.2174/1568026618666180719162124. Review.


Platelet activation markers in children with congenital heart disease associated with pulmonary arterial hypertension.

Mese T, Guven B, Yilmazer MM, Karadeniz C, Ozdemir R, Doksoz O.

Congenit Heart Dis. 2018 Jul;13(4):506-511. doi: 10.1111/chd.12616. Epub 2018 Jul 17.


Pulmonary Arterial Hypertension Associated With the Chinese Herb Indigo Naturalis for Ulcerative Colitis: It May Be Reversible.

Nishio M, Hirooka K, Doi Y.

Gastroenterology. 2018 Aug;155(2):577-578. doi: 10.1053/j.gastro.2018.04.038. Epub 2018 Jul 10. No abstract available.


Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension.

Sugino K, Kabuki T, Shibuya K, Homma S.

BMJ Case Rep. 2018 May 26;2018. pii: bcr-2017-221755. doi: 10.1136/bcr-2017-221755.


Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?

Leary PJ, Kolb TM, Maron BA, Tedford RJ, Zamanian RT.

Int J Cardiol. 2018 Aug 1;264:188. doi: 10.1016/j.ijcard.2018.03.130. No abstract available.


Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?

Wang T, Chen L, Yuan M, Wang J, Lu W.

Int J Cardiol. 2018 Aug 1;264:187. doi: 10.1016/j.ijcard.2018.02.005. No abstract available.


Interpreting risk reduction in clinical trials for pulmonary arterial hypertension.

Lajoie AC, Bonnet S, Lacasse Y, Lega JC, Provencher S.

Eur Respir Rev. 2018 May 15;27(148). pii: 180020. doi: 10.1183/16000617.0020-2018. Print 2018 Jun 30. Review.


Systemic sclerosis: severe pulmonary arterial hypertension and pericardial effusion at diagnosis.

Moniz P, Rei D, Rodrigues J, Botella A.

BMJ Case Rep. 2018 May 14;2018. pii: bcr-2017-223972. doi: 10.1136/bcr-2017-223972.


The role of cardiopulmonary exercise tests in pulmonary arterial hypertension.

Farina S, Correale M, Bruno N, Paolillo S, Salvioni E, Badagliacca R, Agostoni P; “Right and Left Heart Failure Study Group” of the Italian Society of Cardiology.

Eur Respir Rev. 2018 May 2;27(148). pii: 170134. doi: 10.1183/16000617.0134-2017. Print 2018 Jun 30. Review.


Pulmonary Vasoreactivity and Phenotypes in Pulmonary Arterial Hypertension Associated to Connective Tissue Diseases.

Hernández-Oropeza JL, Rodríguez-Reyna TS, Carrillo-Pérez DL, Rodríguez-Andoney JJ, Narváez-David R, Salado-Morales Y, Rivero-Sigarroa E, Domínguez-Cherit G, Pulido-Zamudio T.

Rev Invest Clin. 2018;70(2):82-7. doi: 10.24875/RIC.18002437.


Predictors of poor outcome in patients with pulmonary arterial hypertension: A single center study.

Stepnowska E, Lewicka E, Dąbrowska-Kugacka A, Daniłowicz-Szymanowicz L, Zagożdżon P, Kamiński R, Lewicka-Potocka Z, Miękus P, Kozłowski D, Potocki W, Raczak G.

PLoS One. 2018 Apr 23;13(4):e0193245. doi: 10.1371/journal.pone.0193245. eCollection 2018.


Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts.

Vijarnsorn C, Durongpisitkul K, Chungsomprasong P, Bositthipichet D, Ketsara S, Titaram Y, Chanthong P, Kanjanauthai S, Soongswang J.

PLoS One. 2018 Apr 17;13(4):e0195092. doi: 10.1371/journal.pone.0195092. eCollection 2018.


Unraveling endothelin-1 induced hypercontractility of human pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension.

Wilson JL, Warburton R, Taylor L, Toksoz D, Hill N, Polgar P.

PLoS One. 2018 Apr 12;13(4):e0195780. doi: 10.1371/journal.pone.0195780. eCollection 2018.


Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjögren's syndrome.

Yan S, Li M, Wang H, Yang X, Zhao J, Wang Q, Liu Y, Lai J, Tian Z, Song H, Zhao Y, Zeng X.

Int J Rheum Dis. 2018 May;21(5):1068-1075. doi: 10.1111/1756-185X.13290. Epub 2018 Apr 6.


Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)-An open-label, single-arm study.

Mihara K, Ogawa A, Matsubara H, Terao T, Ichikawa Y.

PLoS One. 2018 Apr 2;13(4):e0195195. doi: 10.1371/journal.pone.0195195. eCollection 2018.


Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.


Pulmonary arterial hypertension: pathogenesis and clinical management.

Thenappan T, Ormiston ML, Ryan JJ, Archer SL.

BMJ. 2018 Mar 14;360:j5492. doi: 10.1136/bmj.j5492. Review.


The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis.

Gu ZC, Zhang YJ, Pan MM, Zhang C, Liu XY, Wei AH, Su YJ.

Medicine (Baltimore). 2018 Mar;97(11):e0122. doi: 10.1097/MD.0000000000010122. Review.

Supplemental Content

Loading ...
Support Center